SCHEMBL3860037

SCHEMBL3860037

O=c1ccc(-c2ccccc2)cn1CCOCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
IDH1 O75874 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
PKM P14618 2/20 0.41
CREBBP Q92793 2/20 0.41
TEAD3 Q99594 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.40
NAAA Q02083 1/20 0.40
MKNK1 Q9BUB5 2/20 0.39
MKNK2 Q9HBH9 2/20 0.39
BRD4 O60885 1/20 0.38
IDO1 P14902 1/20 0.38
AGXT P21549 1/20 0.38
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3863044 0.82 LTA4H (0.44) LTA4HMEN1KMT2APKMTEAD3
SCHEMBL13896707 0.80 HRH3 (0.45) MEN1KMT2AIDH1HRH3CREBBP
SCHEMBL5448923 0.76 MKNK1 (0.47) HRH3CREBBPL3MBTL1MKNK1MKNK2
SCHEMBL5445259 0.76 MKNK1 (0.58) IDH1HRH3CREBBPMKNK1MKNK2
SCHEMBL9098293 0.73 LTA4H (0.39) LTA4HMEN1KMT2APKMTEAD3
SCHEMBL16474464 0.72 DRD2 (0.44) MEN1KMT2ACREBBPGAA
SCHEMBL28080832 0.71 LCK (0.44) LTA4HMEN1KMT2APKMTEAD3
SCHEMBL5439773 0.71 CREBBP (0.53) IDH1HRH3CREBBPGAAMKNK1
SCHEMBL5184776 0.70 RAB9A (0.51) LTA4HHRH3L3MBTL1TSHRBRD4
SCHEMBL31086617 0.70 CYP4F2 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314087-B2 Nitrogen-containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2012-11-20 US disclosed
EP-2114898-A2 NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS Amgen Inc. (US) 2009-11-11 EP disclosed
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2008-11-13 US disclosed
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2008-11-13 US disclosed
WO-2008103277-A2 NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS AMGEN INC. (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use HGF, HGFAC, MET LTA4H 1033/4885MEN1 358/4885KMT2A 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.